NANO-PHOTOMED

Targeted Nano-Photomedicines for Multi-spectral Photodynamic Therapy of Cancer

Coordinatore	ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM    more  Organization address address: 's Gravendijkwal 230 city: ROTTERDAM postcode: 3015CE contact info Titolo: Dr. Nome: Dominic Cognome: Robinson Email: send email Telefono: 31104632104 Fax: 31104632141
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	83˙848 €
EC contributo	83˙848 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2007-4-2-IIF
Funding Scheme	MC-IIF
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-09-01   -   2009-08-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM  Organization address address: 's Gravendijkwal 230 city: ROTTERDAM postcode: 3015CE contact info Titolo: Dr. Nome: Dominic Cognome: Robinson Email: send email Telefono: 31104632104 Fax: 31104632141	NL (ROTTERDAM)	coordinator	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'We propose to develop multifunctional, targeted nano-photomedicines that are capable of bypassing biological barriers to deliver nano-engineered photosensitizer drugs and molecular-imaging agents to tumor tissues and angiogenetic micro-vasculature. Specifically, a unique nanomedicine system for targeted multi-spectral photodynamic therapy is proposed. The system consists of (i) luminescent quantumdot (QD) conjugated with photosensitizer (PS) drugs, which can be sensitized at its maximum efficiency using radiations of deep-tissue penetration (ii) molecular-imaging agents for the early stage detection and in situ treatment-effect analysis (iii) active targeting ligands to specifically target tumor and micro-vasculature. During the incoming phase, QDs of ZnS, Y2O3 and Gd2O3 emitting multi-spectral light under excitation with deep high-tissue penetrating radiations will be conjugated with PS so as to sensitize them at their characteristic absorption using Fluorescent Resonant Energy Transfer (FRET). The QD-PS will be combined with MRI contrast agents using `core/shell’ nanotechnology and made water soluble by capping with polyethylene glycol (PEG). Finally, the nanomedicine will be connected with tumor specific ligands such as folic acid, MAbs and peptides. Optimization of nanomedicine will be carried out by studying dark and photo-toxicity in normal and cancer cell-lines in vitro. Photodynamic treatment will be carried out in pre-clinical animal models using multispectral radiations under different photo- and drug-dose conditions, followed by molecular imaging (MRI) based estimation of PDT response-dose inter-relationships. During the return phase, scanning probe imaging based investigations on the mechanism-of-activity of nano-photomedicines at intra-cellular regions leading to cell-death (apoptosis) will be investigated.'